Top Pharmaceutical Stocks Worth Watching – February 03rd

Eli Lilly and Company, AbbVie, Pfizer, Amgen, Gilead Sciences, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the seven Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks refer to shares of companies that are involved in the research, development, manufacturing, and sale of drugs and medications. These stocks are part of the healthcare sector and are influenced by factors such as demand for new treatments, regulatory approvals, and market competition. Investors may choose to invest in pharmaceutical stocks to capitalize on the potential growth and profitability of these companies within the healthcare industry. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of NYSE:LLY traded up $1.79 on Monday, hitting $812.87. The company had a trading volume of 1,659,038 shares, compared to its average volume of 3,746,219. The business has a 50 day moving average of $783.56 and a 200 day moving average of $843.75. Eli Lilly and Company has a 52-week low of $682.53 and a 52-week high of $972.53. The company has a market cap of $771.67 billion, a PE ratio of 87.80, a PEG ratio of 1.72 and a beta of 0.42. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE:ABBV traded up $6.27 during trading on Monday, reaching $190.17. The stock had a trading volume of 4,944,873 shares, compared to its average volume of 6,142,107. AbbVie has a fifty-two week low of $153.58 and a fifty-two week high of $207.32. The stock has a market cap of $336.06 billion, a P/E ratio of 79.19, a PEG ratio of 1.84 and a beta of 0.58. The business has a fifty day moving average price of $176.57 and a 200-day moving average price of $185.13. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64.

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

NYSE PFE traded down $0.28 during trading hours on Monday, hitting $26.25. 25,257,766 shares of the company’s stock were exchanged, compared to its average volume of 35,336,590. The firm has a market capitalization of $148.73 billion, a P/E ratio of 35.48, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. Pfizer has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business’s 50 day moving average is $26.27 and its 200-day moving average is $27.85.

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

NASDAQ:AMGN traded up $3.49 during trading hours on Monday, reaching $288.91. 2,147,819 shares of the company were exchanged, compared to its average volume of 3,013,767. Amgen has a 52-week low of $253.30 and a 52-week high of $346.85. The firm has a market cap of $155.30 billion, a price-to-earnings ratio of 37.00, a PEG ratio of 2.87 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The stock has a 50 day simple moving average of $271.06 and a 200 day simple moving average of $304.11.

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Shares of NASDAQ GILD traded up $1.53 during midday trading on Monday, hitting $98.73. The stock had a trading volume of 5,720,572 shares, compared to its average volume of 6,770,705. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $99.45. The company has a market capitalization of $123.04 billion, a price-to-earnings ratio of 1,097.01, a PEG ratio of 1.37 and a beta of 0.18. The company has a fifty day moving average price of $92.42 and a 200 day moving average price of $85.96.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

VRTX stock traded up $7.29 during midday trading on Monday, reaching $468.97. 1,198,451 shares of the company’s stock traded hands, compared to its average volume of 1,563,814. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The business has a 50-day moving average price of $434.55 and a two-hundred day moving average price of $462.75. The company has a market capitalization of $120.77 billion, a P/E ratio of -236.09, a PEG ratio of 2.39 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of NYSE TMO traded down $1.82 on Monday, hitting $595.93. The company had a trading volume of 920,805 shares, compared to its average volume of 2,055,506. The firm has a market capitalization of $227.94 billion, a P/E ratio of 36.06, a PEG ratio of 4.06 and a beta of 0.77. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific has a 12-month low of $493.30 and a 12-month high of $627.88. The business has a 50 day moving average of $541.37 and a two-hundred day moving average of $571.18.